NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received an average recommendation of “Hold” from the twelve brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $13.8571.

A number of research analysts recently issued reports on NEO shares. Benchmark upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Wednesday, April 29th. TD Cowen lifted their price target on shares of NeoGenomics from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Zacks Research downgraded shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 20th. UBS Group reiterated a “hold” rating on shares of NeoGenomics in a research note on Wednesday, February 18th. Finally, Needham & Company LLC lifted their price target on shares of NeoGenomics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th.

Institutional Trading of NeoGenomics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEO. First Trust Advisors LP acquired a new stake in NeoGenomics during the first quarter worth approximately $45,725,000. First Light Asset Management LLC raised its holdings in NeoGenomics by 45.0% during the third quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock worth $76,639,000 after purchasing an additional 3,080,837 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in NeoGenomics during the fourth quarter worth approximately $19,182,000. American Capital Management Inc. raised its holdings in NeoGenomics by 120.9% during the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock worth $18,105,000 after purchasing an additional 1,283,390 shares in the last quarter. Finally, Aberdeen Group plc raised its holdings in NeoGenomics by 127.1% during the fourth quarter. Aberdeen Group plc now owns 1,798,939 shares of the medical research company’s stock worth $21,156,000 after purchasing an additional 1,006,676 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Stock Down 1.4%

Shares of NeoGenomics stock opened at $8.24 on Friday. NeoGenomics has a 52-week low of $4.72 and a 52-week high of $13.74. The company has a 50 day moving average of $8.27 and a 200 day moving average of $10.34. The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $1.07 billion, a P/E ratio of -10.70 and a beta of 1.81.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.01. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. The company had revenue of $186.67 million during the quarter, compared to the consensus estimate of $184.54 million. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. As a group, research analysts forecast that NeoGenomics will post -0.15 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.